- Home
- U vs EXEL Comparison
U vs EXEL Comparison
Compare U & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- U
- EXEL
- Stock Information
- Founded
- U 2004
- EXEL 1994
- Country
- U United States
- EXEL United States
- Employees
- U N/A
- EXEL N/A
- Industry
- U Retail: Computer Software & Peripheral Equipment
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- U Technology
- EXEL Health Care
- Exchange
- U Nasdaq
- EXEL Nasdaq
- Market Cap
- U 9.5B
- EXEL 10.0B
- IPO Year
- U 2020
- EXEL 2000
- Fundamental
- Price
- U $22.47
- EXEL $33.29
- Analyst Decision
- U Hold
- EXEL Buy
- Analyst Count
- U 15
- EXEL 16
- Target Price
- U $23.18
- EXEL $32.75
- AVG Volume (30 Days)
- U 11.8M
- EXEL 2.1M
- Earning Date
- U 11-07-2024
- EXEL 02-04-2025
- Dividend Yield
- U N/A
- EXEL N/A
- EPS Growth
- U N/A
- EXEL 441.02
- EPS
- U N/A
- EXEL 1.55
- Revenue
- U $1,965,424,000.00
- EXEL $2,081,598,000.00
- Revenue This Year
- U N/A
- EXEL $20.59
- Revenue Next Year
- U $1.10
- EXEL $1.50
- P/E Ratio
- U N/A
- EXEL $21.51
- Revenue Growth
- U N/A
- EXEL 17.31
- 52 Week Low
- U $13.90
- EXEL $19.20
- 52 Week High
- U $43.54
- EXEL $36.97
- Technical
- Relative Strength Index (RSI)
- U 43.66
- EXEL 40.46
- Support Level
- U $26.06
- EXEL $34.58
- Resistance Level
- U $28.67
- EXEL $36.22
- Average True Range (ATR)
- U 1.67
- EXEL 0.80
- MACD
- U -0.58
- EXEL -0.44
- Stochastic Oscillator
- U 11.17
- EXEL 5.79
About U Unity Software Inc.
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.